Ocugen (OCGN) Projected to Announce Quarterly Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Ocugen to post earnings of ($0.06) per share and revenue of $1.32 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $0.89 million. On average, analysts expect Ocugen to post ($0.25) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Ocugen Stock Up 3.6%

Shares of OCGN stock opened at $0.79 on Wednesday. The company has a 50-day simple moving average of $1.07 and a two-hundred day simple moving average of $1.44. Ocugen has a 52-week low of $0.70 and a 52-week high of $2.73.

Insider Transactions at Ocugen

In other news, CEO Shankar Musunuri sold 468,727 shares of the stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $0.95, for a total transaction of $445,290.65. Following the sale, the chief executive officer owned 4,018,470 shares in the company, valued at $3,817,546.50. This represents a 10.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,051,982 shares of company stock valued at $1,088,801 over the last three months. 3.95% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Weiss Ratings raised shares of Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Wall Street Zen downgraded shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.50.

About Ocugen

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company’s programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen’s pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.